Literature DB >> 11063390

Cyclooxygenase-2-dependent prostaglandin production by peripheral blood monocytes stimulated with lipopolysaccharides isolated from periodontopathogenic bacteria.

K Noguchi1, M Yanai, M Shitashige, T Nishihara, I Ishikawa.   

Abstract

BACKGROUND: Prostaglandin E2 (PGE2) plays important roles in the pathogenesis of periodontal disease. Recent studies have revealed the existence of 2 isozymes of cyclooxygenase (COX), called COX-1 and COX-2. The purpose of the present study was to investigate the contribution of COX-1 and COX-2 to PGE2 production by human peripheral blood monocytes that are stimulated with lipopolysaccharides (LPS) from periodontopathogenic bacteria.
METHODS: LPS were isolated from Actinobacillus actinomycetemcomitans (A. actinomycetemcomitans) and Porphyromonas gingivalis (P. gingivalis) by the phenol-water method. Peripheral blood monocytes were stimulated with LPS for the indicated periods, and the levels of PGE2 or interleukin (IL)-1 beta in the culture media were measured by enzyme-linked immunosorbent assay. Expression of COX-1 and -2 proteins was studied by immunocytochemical staining, and COX-2 mRNA expression was examined by Northern blot analysis.
RESULTS: Peripheral blood monocytes stimulated with A. actinomycetemcomitans- or P. gingivalis-LPS produced PGE2 in a time- and dose-dependent manner. Indomethacin, a non-selective COX-1/COX-2 inhibitor, and NS-398, a specific COX-2 inhibitor, completely inhibited PGE2 production. Immunocytochemical staining of COX-1 and COX-2 proteins showed that expression of COX-2 protein was increased in monocytes that were stimulated with A. actinomycetemcomitans- or P. gingivalis-LPS, compared with that in unstimulated monocytes, whereas expression of COX-1 protein was not altered. Northern blot analysis showed that monocytes stimulated with A. actinomycetemcomitans- or P. gingivalis-LPS expressed COX-2 mRNA, while COX-2 mRNA was not detectable in unstimulated cells. Treatment of A. actinomycetemcomitans-LPS-stimulated monocytes with NS-398 induced a significant increase of IL-1 beta production to the same extent as treatment with indomethacin.
CONCLUSIONS: These results suggest that COX-2 is induced in monocytes stimulated with LPS derived from A. actinomycetemcomitans and P. gingivalis and that the COX-2 is primarily responsible for PGE2 production. COX-2 may be pivotal in PGE2 production in periodontal lesions and may be involved in inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063390     DOI: 10.1902/jop.2000.71.10.1575

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  5 in total

1.  The effect of low-level diode laser on COX-2 gene expression in chronic periodontitis patients.

Authors:  Snezana Pesevska; Icko Gjorgoski; Kiro Ivanovski; Nikolaos K Soldatos; Nikola Angelov
Journal:  Lasers Med Sci       Date:  2017-05-18       Impact factor: 3.161

2.  Effects of the antimicrobial peptide cathelicidin (LL-37) on immortalized gingival fibroblasts infected with Porphyromonas gingivalis and irradiated with 625-nm LED light.

Authors:  JiSun Kim; SangWoo Kim; WonBong Lim; HongRan Choi; OkJoon Kim
Journal:  Lasers Med Sci       Date:  2014-12-28       Impact factor: 3.161

3.  Effect of IL-15 and natural killer cells on osteoclasts and osteoblasts in a mouse coculture.

Authors:  Hiroaki Takeda; Takeshi Kikuchi; Kyoko Soboku; Iichiro Okabe; Hiroki Mizutani; Akio Mitani; Yuichi Ishihara; Toshihide Noguchi
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

4.  Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.

Authors:  Jonathan M Gitlin; Charles D Loftin
Journal:  Cardiovasc Res       Date:  2008-10-22       Impact factor: 10.787

5.  Alteration of PTGS2 promoter methylation in chronic periodontitis.

Authors:  S Zhang; S P Barros; M D Niculescu; A J Moretti; J S Preisser; S Offenbacher
Journal:  J Dent Res       Date:  2009-12-30       Impact factor: 6.116

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.